Can-Fite BioPharma (NYSEAMERICAN:CANF) received a $7.00 target price from investment analysts at Maxim Group in a research report issued to clients and investors on Monday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s target price would suggest a potential upside of 340.25% from the company’s current price.
A number of other equities analysts have also recently commented on CANF. ValuEngine cut Can-Fite BioPharma from a “sell” rating to a “strong sell” rating in a report on Thursday, September 7th. HC Wainwright set a $6.00 price target on Can-Fite BioPharma and gave the stock a “buy” rating in a report on Tuesday, October 31st.
Can-Fite BioPharma (NYSEAMERICAN CANF) opened at $1.59 on Monday. Can-Fite BioPharma has a 1-year low of $1.24 and a 1-year high of $2.67.
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.